Lusong Luo

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition

Zhan Yao, Neilawattie M. Torres, Anthony Tao et al. · Cancer Cell · 2015 · 537 citations · Full text

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Steven D. Knight, Nicholas D. Adams, Joelle L. Burgess et al. · ACS Medicinal Chemistry Letters · 2010 · 367 citations · Full text

Highly Potent Inhibitor, Tumor Biology, Mammalian Target +16

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase

Yunhang Guo, Ye Liu, Nan Hu et al. · Journal of Medicinal Chemistry · 2019 · 332 citations · Full text

Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic <i>BRAF</i> by the Kinase Inhibitor SB-590885

Alastair J. King, Denis R. Patrick, Roberta S. Batorsky et al. · Cancer Research · 2006 · 262 citations · Full text

Pathology, Oncogenic Braf Alleles, Tumor Biology +17

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E

Kenneth W. Wood, Latesh Lad, Lusong Luo et al. · Proceedings of the National Academy of Sciences · 2010 · 252 citations · Full text

Antitumor Activity, Cenp-e Motor Activity, Molecular Biology +18